Trial Profile
A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Docetaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 01 Mar 2012 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 25 Jan 2011 Results presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ACSO), according to a PharmaEngine media release
- 25 Jan 2011 Primary endpoint 'Objective-clinical-response-rate' has been met